Meeder Advisory Services Inc. Grows Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Meeder Advisory Services Inc. raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,148 shares of the medical research company’s stock after purchasing an additional 169 shares during the period. Meeder Advisory Services Inc.’s holdings in IQVIA were worth $796,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of IQVIA by 4.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock worth $532,070,000 after buying an additional 93,194 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of IQVIA by 339.6% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after buying an additional 1,597,003 shares during the period. Capital Research Global Investors increased its holdings in shares of IQVIA by 42.2% in the fourth quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock worth $461,675,000 after buying an additional 592,372 shares during the period. Norges Bank purchased a new position in shares of IQVIA in the fourth quarter worth about $383,705,000. Finally, Morningstar Investment Services LLC increased its holdings in shares of IQVIA by 96.9% in the fourth quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock worth $286,704,000 after buying an additional 606,333 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Monday. Robert W. Baird cut their target price on IQVIA from $241.00 to $235.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. Truist Financial cut their target price on IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a research note on Friday, May 3rd. Barclays cut their target price on IQVIA from $275.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, June 28th. Finally, Evercore ISI cut their target price on IQVIA from $250.00 to $230.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 9th. Three investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $255.73.

IQVIA Stock Up 2.0 %

Shares of IQV stock traded up $4.55 during trading hours on Tuesday, hitting $230.44. 140,331 shares of the company’s stock traded hands, compared to its average volume of 1,058,925. The stock’s fifty day simple moving average is $219.69 and its two-hundred day simple moving average is $228.91. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The stock has a market cap of $41.99 billion, a price-to-earnings ratio of 30.86, a PEG ratio of 2.04 and a beta of 1.49. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.11. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The firm had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. On average, analysts expect that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.